NCIC Clinical Trials Group: Prostatic Neoplasms trials

The registry lists 13 Prostatic Neoplasms studies with NCIC Clinical Trials Group as lead sponsor. 0 are open to participants now and 2 have results posted.

Phase 1 2Phase 2 5Phase 3 5No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate CancerCompletedNCT01331083Phase 2Results posted
• Observation or Radical Treatment in Patients With Prostate CancerTerminatedNCT00499174Not applicableResults posted
• SB939 in Treating Patients With Recurrent or Metastatic Prostate CancerCompletedNCT01075308Phase 2
• Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate CancerTerminatedNCT00651326Phase 3
• OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid TumorsCompletedNCT00471432Phase 1
• Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone TherapyCompletedNCT00258388Phase 2
• Sorafenib in Treating Patients With Metastatic or Recurrent Prostate CancerCompletedNCT00093457Phase 2
• Vitamin E, Selenium, and Soy Protein in Preventing Cancer in Patients With High-Grade Prostate NeoplasiaCompletedNCT00064194Phase 3
• Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate CancerCompletedNCT00054106Phase 1
• ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00025116Phase 2
• Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate CancerCompletedNCT00003653Phase 3
• Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate CancerCompletedNCT00003232Phase 3
• Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate CancerCompletedNCT00002633Phase 3